2002
DOI: 10.1002/art.10227
|View full text |Cite
|
Sign up to set email alerts
|

Viral interleukin‐10 gene inhibition of inflammation, osteoclastogenesis, and bone resorption in response to titanium particles

Abstract: Objective. To evaluate the potential of viral interleukin-10 (vIL-10) gene therapy as an approach to prevent wear debris-induced inflammation, osteoclastogenesis, and bone resorption as it relates to periprosthetic osteolysis in patients with total joint replacements.Methods. Replication-defective adenovirus vectors expressing vIL-10 (AdvIL-10) or LacZ (AdLacZ) target genes were used to transduce fibroblast-like synoviocytes (FLS) in vitro, and the effects of these cells on wear debris-induced proinflammatory … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
43
0
2

Year Published

2004
2004
2012
2012

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 75 publications
(47 citation statements)
references
References 61 publications
1
43
0
2
Order By: Relevance
“…35 In this study, elevated vIL-10 expression dramatically reduced the incidence of bone pit erosions and bone collagen degradation, along with marked anti-inflammatory effects. Carmody et al 22 recently published findings, which show that systemic viral IL-10 gene transfer completely blocked titanium particle-induced calvaria bone resorption, which is in agreement with current results. …”
Section: Discussionsupporting
confidence: 92%
See 1 more Smart Citation
“…35 In this study, elevated vIL-10 expression dramatically reduced the incidence of bone pit erosions and bone collagen degradation, along with marked anti-inflammatory effects. Carmody et al 22 recently published findings, which show that systemic viral IL-10 gene transfer completely blocked titanium particle-induced calvaria bone resorption, which is in agreement with current results. …”
Section: Discussionsupporting
confidence: 92%
“…Blocking these processes may provide potential therapeutic approaches to prevent or retard the periprosthetic osteolysis and prolong the life of prostheses. 22 We have proposed that the inhibition of proinflammatory cytokines represents a potential therapy to reduce chronic inflammation provoked by wear debris in the periprosthetic tissue. Current systemic anti-inflammation therapies have several weaknesses, including high-dose requirements with modest efficiency, systemic side effects, and tendency for poor patient compliance.…”
Section: Discussionmentioning
confidence: 99%
“…41 IL-6 (-/-) and IL-1R (-/-) mice. In terms of drug and gene therapy, several substances have been evaluated: alendronate and pentoxifylline, 30 etanercept celecoxib, 39 RANK:Fc, 41 OPG, 42,43 TNFR:Fc, 40 viral IL (vIL)-10 44 anti-IL-6 and anti-IL-1R. These have elucidated the biological hierarchy in which RANK blockade is clearly the safest and most effective means to prevent and ameliorate wear debris-induced osteolysis.…”
Section: Potential Therapeutic Interventionsmentioning
confidence: 99%
“…Furthermore, the incidence of bone pit erosions and bone collagen degradation was dramatically reduced. Carmody and colleagues 44 used replication-defective adenovirus vectors expressing vIL-10 (AdvIL-10) or LacZ (AdLacZ) target genes to transduce fibroblast-like synoviocytes (FLS) in vitro to evaluate wear debris-induced osteolysis in a mouse calvaria model. In the presence of AdLacZ-infected FLS, titanium particle-stimulated macrophages exhibited a marked increase in secretion of TNFα (6.5-fold), IL-6 (13-fold) and IL-1 (5-fold).…”
Section: Potential Therapeutic Interventionsmentioning
confidence: 99%
“…79,80 In the air pouch study, an investigation of mRNA expression using real-time PCR was conducted to determine whether anti-inflammatory gene therapy affects cytokine gene expression. IL-1, IL-6 and TNF gene expression were readily detected by the technique, and IL-1 was observed to be the predominant cytokine expressed in response to UHMWPE particle stimulation.…”
Section: Gene Therapymentioning
confidence: 99%